Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.72 |
| ▸ | GAA | P10253 | 2/20 | 0.72 |
| ▸ | RAB9A | P51151 | 1/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | FFAR2 | O15552 | 6/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23910562 | 1.00 | POLB (0.72) | POLBGAARAB9AHSD17B10FFAR2 | |
| SCHEMBL4350452 | 1.00 | POLB (0.72) | POLBGAARAB9AHSD17B10FFAR2 | |
| SCHEMBL9853999 | 0.85 | POLB (0.58) | POLBGAARAB9AHSD17B10FFAR2 | |
| Acetic Acid SCHEMBL9854087 | 0.84 | POLB (0.57) | POLBGAARAB9AHSD17B10FFAR2 | |
| SCHEMBL11718542 | 0.84 | POLB (0.60) | POLBGAARAB9AHSD17B10FFAR2 | |
| SCHEMBL11718548 | 0.84 | POLB (0.60) | POLBGAARAB9AHSD17B10FFAR2 | |
| SCHEMBL11385050 | 0.83 | ACE (0.61) | POLBGAARAB9AHSD17B10FFAR2 | |
| SCHEMBL9149937 | 0.81 | POLB (0.54) | POLBGAARAB9AHSD17B10FFAR2 | |
| SCHEMBL8870565 | 0.81 | HSD17B10 (0.57) | POLBGAARAB9AHSD17B10FFAR2 | |
| SCHEMBL8871013 | 0.81 | HSD17B10 (0.57) | POLBGAARAB9AHSD17B10FFAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3727314-B1 | DEODORANT COMPOSITIONS | UNILEVER IP HOLDINGS B V (NL) | 2021-10-13 | — | — | EP | claimed |
| US-20200383891-A1 | DEODORANT COMPOSITIONS | CONOPCO, INC., D/B/A UNILEVER (US) | 2020-12-10 | — | — | US | claimed |
| EP-3727314-A1 | DEODORANT COMPOSITIONS | Unilever PLC (GB) | 2020-10-28 | — | — | EP | claimed |
| US-12246081-B2 | Deodorant compositions | CONOPCO, INC. (US) | 2025-03-11 | — | — | US | disclosed |
| EP-3727314-B1 | DEODORANT COMPOSITIONS | UNILEVER IP HOLDINGS B V (NL) | 2021-10-13 | — | — | EP | disclosed |
| US-20200383891-A1 | DEODORANT COMPOSITIONS | CONOPCO, INC., D/B/A UNILEVER (US) | 2020-12-10 | — | — | US | disclosed |
| EP-3727314-A1 | DEODORANT COMPOSITIONS | Unilever PLC (GB) | 2020-10-28 | — | — | EP | disclosed |
| US-6989384-B2 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. (US) | 2006-01-24 | — | — | US | disclosed |
| US-20050080121-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. | 2005-04-14 | — | — | US | disclosed |
| EP-1355878-A2 | ANTIPICORNAVIRAL COMPOUNDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND MATERIALS FOR THEIR SYNTHESIS | AGOURON PHARMACEUTICALS, INC. (US) | 2003-10-29 | — | — | EP | disclosed |
| US-6632825-B2 | Picornaviral 3C protease enzyme inhibitors; amide ester or amide acid derivatives | AGOURON PHARMACEUTICALS, INC. | 2003-10-14 | — | — | US | disclosed |
| US-20020061916-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. | 2002-05-23 | — | — | US | disclosed |
| WO-2001096297-A2 | ANTIPICORNAVIRAL COMPOUNDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND MATERIALS FOR THEIR SYNTHESIS | AGOURON PHARMACEUTICALS, INC. (US) | 2001-12-20 | — | — | WO | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| US-6197794-B1 | ANTIINFLAMAMTORY AGENTS; IMMUNOLOGY DISEASES | CELLTECH THERAPEUTICS LIMITED (GB) | 2001-03-06 | — | — | US | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| US-5385922-A | Cardiovascular and gastrointestinal disorders; antiischemic and cardiotonic agents | CEDONA PHARMACEUTICALS B.V. (NL) | 1995-01-31 | — | — | US | disclosed |
| EP-0547104-A1 | THIAZOLIDIN DERIVATIVES | CEDONA PHARMACEUTICALS B.V. (NL) | 1993-06-23 | — | — | EP | disclosed |
| WO-1992004337-A1 | THIAZOLIDIN DERIVATIVES | CEDONA PHARMACEUTICALS BV (NL) | 1992-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080121-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | PRCP, RNPEP, SARNP | POLB 505/4885GAA 554/4885RAB9A 2493/4885 |
| US-12246081-B2 | Deodorant compositions | DHODH, STS, DDT | POLB 1758/4885GAA 129/4885RAB9A 2248/4885 |
| US-20020061916-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | PRCP, RNASEL, RNASEH1 | POLB 445/4885GAA 477/4885RAB9A 2679/4885 |
| US-20200383891-A1 | DEODORANT COMPOSITIONS | DHODH, STS, DDT | POLB 1758/4885GAA 129/4885RAB9A 2248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.